Advances in Combination Therapy for Asthma and COPD
John Wiley & Sons, Nov 28, 2011 - Medical - 352 pages
Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy for Asthma and COPD is the first book to address the complexity of multi-agent therapy and deal with management issues in an integrated fashion. A review of currently available agents and their applications, as well as new therapies soon to become available are outlined. Advantages of combined therapies and additional considerations that arise from multi-agent programs are highlighted.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Novel antiinflammatory treatments for asthma and COPD 154
Novel biologicals alone and in combination
Antiinfective treatments in asthma and COPD 232
Longacting muscarinic antagonists in asthma and COPD 268
Phosphodiesterase inhibitors in obstructive lung disease 296
Biological therapies in development for COPD 311
Other editions - View all
1:17 Printer Name 10:5 Printer Name 2-adrenoceptor 2-agonists activation agonists airway inflammation airway smooth muscle allergen Allergy Allergy Clin Immunol antibiotics antibody anticholinergic asthma and COPD asthma control asthma exacerbations Barnes PJ beta-agonist binding bronchial bronchodilator budesonide chemokines chronic obstructive pulmonary clinical trials combination therapy compared COPD patients cytokines doses drugs efficacy eosinophils epithelial cells FEV1 fluticasone propionate formoterol glucocorticoid receptor GM-CSF histone human ICS therapy improvement increased indacaterol induced infection inflammation infliximab inhaled corticosteroids inhibition interaction interleukin JWST083-08 JWST083-L¨otvall September JWST083-L¨otvall September 22 kinase LABA LABA therapy long-acting lung function macrophages mast cells mechanisms mediators neutrophils NF-B obstructive pulmonary disease omalizumab patients with asthma patients with COPD PDE4 inhibitors persistent asthma Pharmacol pharmacological placebo placebo-controlled pneumoniae protein randomized reduced Respir Respir Crit respiratory response roflumilast role salbutamol salmeterol September 22 severe asthma smooth muscle sputum steroid symptoms T-cells therapeutic Thorax tiotropium treatment